The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956.


After 20 years follow-up of newly diagnosed patients with Parkinson's disease (PD), 100 of 136 (74%) have died. The mortality rate fell in the first 3 years of treatment, then rose compared to the general population, the standardized mortality ratio from 15 to 20 years reaching 3.1. Drug induced dyskinesia and end of dose failure were experienced by most patients, but the main current problems relate to the non-levodopa responsive features of the disease. Dementia is present in 83% of 20-year survivors. Dementia correlates with increasing age and probably reflects an interplay of multiple pathologies. Seventeen people with dementia had postmortems. Eight had diffuse Lewy bodies as the only cause of dementia, while others had mixed neuropathology. Only one person lives independently and 48% are in nursing homes. Excessive daytime sleepiness is noted in 70%, falls have occurred in 87%, freezing in 81%, fractures in 35%, symptomatic postural hypotension in 48%, urinary incontinence in 71%, moderate dysarthria in 81%, choking in 48%, and hallucinations in 74%. The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living
  • Adult
  • Aged
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use
  • Australia
  • Dementia / epidemiology*
  • Dementia / etiology*
  • Dyskinesias / epidemiology
  • Female
  • Follow-Up Studies
  • Hallucinations / etiology
  • Humans
  • Levodopa / adverse effects
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / mortality
  • Parkinson Disease / physiopathology
  • Parkinson Disease / psychology*
  • Time Factors


  • Antiparkinson Agents
  • Levodopa